254 related articles for article (PubMed ID: 16498395)
1. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia.
Campbell LJ; Fidler C; Eagleton H; Peniket A; Kusec R; Gal S; Littlewood TJ; Wainscoat JS; Boultwood J
Leukemia; 2006 Apr; 20(4):671-9. PubMed ID: 16498395
[TBL] [Abstract][Full Text] [Related]
2. Expression of telomeric repeat binding factor 1 and 2 and TRF1-interacting nuclear protein 2 in human gastric carcinomas.
Matsutani N; Yokozaki H; Tahara E; Tahara H; Kuniyasu H; Haruma K; Chayama K; Yasui W; Tahara E
Int J Oncol; 2001 Sep; 19(3):507-12. PubMed ID: 11494028
[TBL] [Abstract][Full Text] [Related]
3. Dysregulated expression of the major telomerase components in leukaemic stem cells.
Drummond MW; Hoare SF; Monaghan A; Graham SM; Alcorn MJ; Keith WN; Holyoake TL
Leukemia; 2005 Mar; 19(3):381-9. PubMed ID: 15674365
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.
Roy S; Jørgensen HG; Roy P; Abed El Baky M; Melo JV; Strathdee G; Holyoake TL; Bartholomew C
Br J Haematol; 2012 May; 157(4):446-56. PubMed ID: 22372463
[TBL] [Abstract][Full Text] [Related]
5. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.
Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA
Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644
[TBL] [Abstract][Full Text] [Related]
6. Role of human telomerase reverse transcriptase and telomeric-repeat binding factor proteins 1 and 2 in human hematopoietic cells.
Yamada K; Yajima T; Yagihashi A; Kobayashi D; Koyanagi Y; Asanuma K; Yamada M; Moriai R; Kameshima H; Watanabe N
Jpn J Cancer Res; 2000 Dec; 91(12):1278-84. PubMed ID: 11123427
[TBL] [Abstract][Full Text] [Related]
7. Telomerase activity in B-cell non-Hodgkin lymphomas is regulated by hTERT transcription and correlated with telomere-binding protein expression but uncoupled from proliferation.
Klapper W; Krams M; Qian W; Janssen D; Parwaresch R
Br J Cancer; 2003 Aug; 89(4):713-9. PubMed ID: 12915884
[TBL] [Abstract][Full Text] [Related]
8. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
9. BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia.
Gonzalez MS; De Brasi CD; Bianchini M; Gargallo P; Moiraghi B; Bengió R; Larripa IB
Blood Cells Mol Dis; 2010 Oct; 45(3):192-6. PubMed ID: 20728382
[TBL] [Abstract][Full Text] [Related]
10. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1.
Yamada O; Ozaki K; Furukawa T; Machida M; Wang YH; Motoji T; Mitsuishi T; Akiyama M; Yamada H; Kawauchi K; Matsuoka R
Cell Signal; 2011 Jul; 23(7):1119-27. PubMed ID: 21356308
[TBL] [Abstract][Full Text] [Related]
11. Role of hTERT and WT1 gene expression in disease progression and imatinib responsiveness of patients with BCR-ABL positive chronic myeloid leukemia.
Varma N; Anand MS; Varma S; Juneja SS
Leuk Lymphoma; 2011 Apr; 52(4):687-93. PubMed ID: 21314483
[TBL] [Abstract][Full Text] [Related]
12. Elevated telomerase activity, c-MYC-, and hTERT mRNA expression: association with tumour progression in malignant lipomatous tumours.
Schneider-Stock R; Boltze C; Jäger V; Epplen J; Landt O; Peters B; Rys J; Roessner A
J Pathol; 2003 Apr; 199(4):517-25. PubMed ID: 12635143
[TBL] [Abstract][Full Text] [Related]
13. Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy.
Keller G; Brassat U; Braig M; Heim D; Wege H; Brümmendorf TH
Hematol Oncol; 2009 Sep; 27(3):123-9. PubMed ID: 19569255
[TBL] [Abstract][Full Text] [Related]
14. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
[TBL] [Abstract][Full Text] [Related]
15. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
16. A balanced transcription between telomerase and the telomeric DNA-binding proteins TRF1, TRF2 and Pot1 in resting, activated, HTLV-1-transformed and Tax-expressing human T lymphocytes.
Escoffier E; Rezza A; Roborel de Climens A; Belleville A; Gazzolo L; Gilson E; Duc Dodon M
Retrovirology; 2005 Dec; 2():77. PubMed ID: 16354306
[TBL] [Abstract][Full Text] [Related]
17. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
18. Antisense inhibition of Bcr-Abl/c-Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells.
Bakalova R; Ohba H; Zhelev Z; Kubo T; Fujii M; Ishikawa M; Shinohara Y; Baba Y
FEBS Lett; 2004 Apr; 564(1-2):73-84. PubMed ID: 15094045
[TBL] [Abstract][Full Text] [Related]
19. Telomerase activity is down regulated via decreases in hTERT mRNA but not TEP1 mRNA or hTERC during the differentiation of leukemic cells.
Koyanagi Y; Kobayashi D; Yajima T; Asanuma K; Kimura T; Sato T; Kida T; Yagihashi A; Kameshima H; Watanabe N
Anticancer Res; 2000; 20(2A):773-8. PubMed ID: 10810353
[TBL] [Abstract][Full Text] [Related]
20. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia.
Primo D; Flores J; Quijano S; Sanchez ML; Sarasquete ME; del Pino-Montes J; Gaarder PI; Gonzalez M; Orfao A
Br J Haematol; 2006 Oct; 135(1):43-51. PubMed ID: 16939497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
